Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

The DEA Wants To Study The Medical Benefits Of Cannabis, But The DOJ Is Stonewalling Them

Aug 16, 2017 • 1:37 PM EDT
TRTC (19).png
3 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Although CNN reported that a study found little evidence that marijuana helps treat chronic pain and PTSD, we beg to differ…

Two studies published in the journal Annals of Internal Medicine found that there was little scientific evidence to support either the effectiveness or safety of medical marijuana.

If Marijuana is Dangerous, Opioids are Nuclear

If the researchers believe medical marijuana is not safe, we would love to know what they think about opiates since they kill more people in one day than marijuana has ever killed (no one has died from overdosing on marijuana).

No one has ever died from smoking marijuana but every year more than half a million people die from alcohol and tobacco.

The authors of the study said, “We found low to moderate-strength evidence that cannabis use is associated with an increased risk for psychotic symptoms, psychosis, mania, and — in active users — short-term cognitive dysfunction.”

Justice Department is Holding Back Key Marijuana Research

Although a lot of the information provided by these research groups said that there needs to be more research conducted in order to have conclusive evidence, the Justice Department under Attorney General Jeff Sessions has made that very difficult.

Earlier this week, The Washington Post reported that the DOJ effectively blocked the Drug Enforcement Administration (DEA) from acting on more than two dozen requests to grow marijuana for research purposes.

In 2016, the DEA began to accept applications to cultivate marijuana for research and as of this month, the agency has 25 proposals to consider; but DEA officials, however advised that they need approval from the DOJ to move forward and the DOJ has not been willing to provide it.

Numbers Don’t Lie…Politicians Do

Research data from a study published in the Journal of the American Medical Association provides evidence that shows that in 2014, states with legal medical cannabis programs had an opioid overdose rate that was 25% lower than the national average.

Cannabis can treat countless debilitating diseases and improve the daily life of millions of people around the world.  Despite all the fake news being reported from the White House pertaining to medical cannabis, the facts don’t lie.

Canadian Firm Helps Support the Need for Cannabis Research

From Israel to Canada, the amount of research and evidence in support of cannabis as a medicine continues to increase.

Canadian-based Canabo Medical (CMM.V: TSX Venture) (CAMDF: OTCQB) is a company leading this initiative. The company has been collecting data on how cannabis interacts with or lessens the need for pharmaceutical treatments. Canabo owns and operates CMClinics, Canada’s largest referral-only clinics for medical cannabis.

In April, Canabo Medical Executive Chairman Neil Smith presented the results from its benzodiazepine study which focused on more than 1,500 patients who started medical cannabinoids while on benzodiazepines. The study found that 40% of patients eliminated the use of benzodiazepines within 90 days. This number increased to 45% within a year of cannabis treatment.

Canabo is currently tracking over 3,500 patients who are taking opioids for a large variety of pain and other disorders. Canabo expects to publish peer-reviewed papers on the opioid-cannabinoid relationship later this year.

It is Time for Action

Joe Rogan said it best: The only reason why marijuana is illegal is because of economics. If marijuana was legal, it would cost pharmaceutical and alcohol companies billions of dollars every year.  The Partnership for a Drug-Free America is funded by alcohol companies. Alcohol is nothing less than a sanctioned drug!

It is time for action and time for the United States to classify marijuana as what it is, a medicine.

Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.